Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Summary

Intensity Therapeutics restarts patient treatment in the INVINCIBLE-4 Phase 2 randomized presurgical trial for triple negative breast cancer, with first patients dosed in Switzerland. The trial restart represents progress in the company's clinical development program for intratumoral cancer therapies.